← Back to front page
Asia · Regional markets · The Financial Express

Biocon gets US FDA approval for cancer biosimilar Pebrilzo; launch expected in 2028

Published by The Financial Express · India 9 h ago
Biocon gets US FDA approval for cancer biosimilar Pebrilzo; launch expected in 2028
The Financial Express

Detailed summary

Biocon wins US FDA approval for cancer biosimilar Pebrilzo, strengthening its oncology portfolio ahead of a 2028 launch; learn more.

Read the full article on The Financial Express Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.financialexpress.com)

Also worth reading